IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Summary

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Timeline

Start

2023-07-13

Primary completion

2026-07-31

Completion

2026-07-31

Drugs

Indications